CAIRDAC, SA, a pre-revenue stage medtech company developing a leadless, self-powered cardiac pacemaker (Autonomous Leadless Pacing System), today announced the appointment of Raymond W. Cohen as chairman of its board of directors.

“We are thrilled to welcome Mr. Cohen to the CAIRDAC board of directors,” said Edouard Fonck, Chief Executive Officer of CAIRDAC, “Ray’s extensive track record in leading, scaling and exiting medical technology companies will, no doubt, be invaluable as we advance this exciting project.”

Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience. He was the co-founder and CEO of Axonics, Inc. (Nasdaq: AXNX) a global leader in implantable neuromodulation devices that completed its initial public offering in 2018. Under his leadership, Axonics was recognized as the fastest-growing technology company in North America generating over $1.2 billion in revenue in the four years from commercial launch. Axonics was acquired by Boston Scientific in late 2024 for $3.7 billion. During 2025, Mr. Cohen, as chairman of SoniVie, Ltd., an Israeli clinical stage company, led the sale of that company for $600 million and later that year, led the sale of Nalu Medical for $533 million.

“I see tremendous commercial potential for leadless pacemaker powered by the movement of the human heart,” said Raymond W. Cohen. “ALPS™ uses a frequency-tuned piezoelectric harvester to convert the mechanical energy of each heartbeat into electricity and store it in an onboard rechargeable battery. By reducing battery-driven constraints, this architecture is designed to support advanced capabilities such as multi-chamber pacing, continuous remote monitoring, diagnostics features and inter-device communication. Bottom line, this technology has the potential to become a new standard of care for patients requiring a cardiac pacemaker."

Cohen currently serves on the boards of several public and private innovative healthcare companies, including Kestra Medical Technologies (Nasdaq: KMTS). Mr. Cohen also serves as an operating partner in the recently established venture fund, Star51 (https://star51capital.com), as well as a venture partner with Andera Partners and Sherpa Capital Partners.

About CAIRDAC
The global pacemaker market is estimated around $5.5 billion. CAIRDAC is developing ALPS™, leadless pacing platform designed to support dual-chamber pacing and future conduction system pacing while reducing reliance on conventional battery-limited architectures. Following preclinical results reported in a 2026 Europace abstract, the company is preparing for its first-in-human study, with a development pathway targeting CE marking in Europe before a U.S. pivotal study. Current investors include Mérieux Equity Partners, Supernova Invest, Bpifrance, Sham Innovation Santé, and Crédit Agricole Touraine et Poitou.

The device is investigational and not yet available for sale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260921216186/en/

Media contact
Laurence Ehringer
Laurence.Ehringer@cairdac.com
+33 1 47 46 85 15
www.cairdac.com

Logo

Tags

More Like This

CardiaCare Completes Seed Extension Raise to Support Clinical Pilot Studies

Heart Failure start-up, Acorai, closes oversubscribed $4m funding round

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved novel wireless system to treat cardiac arrhythmias

BIOTRONIK Expands Cardiac Rhythm Care by Launching World's First CRT-D Systems Approved for Conduction System Pacing

Heart Failure start-up, Acorai, secures €2.3m grant funding from the European Commission

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to implant FDA-approved novel defibrillation lead

Volta Medical Appoints Bill Hoffman as Executive Chairman of the Board of Directors

ONWARD® Medical Announces Changes to Board of Directors, Including Addition of Medtech Leader Rob ten Hoedt as Incoming Chairman